Latest News

GenPro to Present at Biotech Showcase™ Annual Conference on January 9, 2018


Back

Dr. Didier Landais joins Genome Profiling, LLC

As Genome Profiling's Chief Business Officer, Dr. Didier Landais leads GenPro's customer-facing functions including business development, sales, marketing and project management. Didier brings to GenPro over 25 years of broad international experience in the biotech and pharmaceutical industries as an executive leader in research and development, project management, GMP manufacturing, and business development.

Prior to GenPro, Didier served as Project Leader in Oncology at Rhône-Poulenc Rorer's Gene Therapy Division, RPR-Gencell, in Vitry, France now known as Sanofi where he also held scientific positions in AIDS research and oncology. After his MBA, Didier was Senior Director of Business Development at IDM-Pharma and then served as General Manager Cell Therapy where he lead the international development of a cancer vaccine product including clinical trials in the US and Europe and was in charge of IDM-Pharma's alliance with Sanofi-Aventis. He also has served as Chief Development Officer at Biotechnol, as the CEO of Alfact Innovation and as VP Project Management for Innate Pharma. Most recently he has been an Independent Consultant to the bio-pharma and life science research market where Baylor Research Institute, Avesthagen, ImmuPharma and the Carolina Healthcare System are among his clients.

Dr. Landais graduated with a Ph.D. in Molecular and Cellular Biology at University Louis Pasteur, Strasbourg, France, followed by a Post-doctoral internship at UCLA (USA) in Medical Genetic Training Program and an Executive MBA at ESSEC, Paris

For GenPro, Dr. Landais' applies his extensive bio-pharma market knowledge and relationships, particularly in Oncology, and his broad spectrum of skills in research, development, manufacturing, financial planning, intellectual property, and collaboration partnerships to drive Genome Profiling's growth through strategic business alliances with bio-pharma companies, diagnostic companies and clinical research institutions.